Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | HCK | P08631 | 3/20 | 0.33 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.33 |
| ▸ | PRKDC | P78527 | 3/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869327 | 0.80 | PIK3CD (0.34) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL18007681 | 0.78 | MAP3K12 (0.35) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL23851046 | 0.76 | KMT2A (0.36) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL21963189 | 0.75 | CA1 (0.35) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL21962293 | 0.73 | MAP3K12 (0.42) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL20757451 | 0.73 | NLRP3 (0.32) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL20754810 | 0.72 | NLRP3 (0.34) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL21962556 | 0.71 | CA1 (0.36) | CA12CA1CA2CA7 | |
| SCHEMBL26151381 | 0.71 | ABL1 (0.33) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL20757774 | 0.70 | NLRP3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-3883646-A1 | NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-09-29 | — | — | EP | disclosed |
| CN-113164763-A | NLRP3 inhibitor | 英夫拉索姆有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | PIK3CD 3359/4885ABL1 4603/4885EGFR 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.